Chronic Urticaria Or Hives - Pipeline Review, H1 2020

April 2020 | 140 pages | ID: CEA0BB330CEEN
Global Markets Direct

Abstracts

Chronic Urticaria Or Hives - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H1 2020, provides an overview of the Chronic Urticaria Or Hives (Dermatology) pipeline landscape.

Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors include stress, caffeine, warm temperatures, alcohol and insect bites and stings. Treatment includes antihistamines and corticosteroids.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Urticaria Or Hives (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 7, 9, 6, 1 and 1 respectively.

Chronic Urticaria Or Hives (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives (Dermatology).
• The pipeline guide reviews pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Chronic Urticaria Or Hives (Dermatology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Chronic Urticaria Or Hives (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Chronic Urticaria Or Hives (Dermatology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives (Dermatology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Chronic Urticaria Or Hives - Overview
Chronic Urticaria Or Hives - Therapeutics Development
Chronic Urticaria Or Hives - Therapeutics Assessment
Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development
Chronic Urticaria Or Hives - Drug Profiles
Chronic Urticaria Or Hives - Dormant Projects
Chronic Urticaria Or Hives - Discontinued Products
Chronic Urticaria Or Hives - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Chronic Urticaria Or Hives, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Chronic Urticaria Or Hives - Pipeline by Allakos Inc, H1 2020
Chronic Urticaria Or Hives - Pipeline by BiOraliX BV, H1 2020
Chronic Urticaria Or Hives - Pipeline by BiosanaPharma BV, H1 2020
Chronic Urticaria Or Hives - Pipeline by Celldex Therapeutics Inc, H1 2020
Chronic Urticaria Or Hives - Pipeline by Celltrion Inc, H1 2020
Chronic Urticaria Or Hives - Pipeline by Eli Lilly and Co, H1 2020
Chronic Urticaria Or Hives - Pipeline by ELORAC Inc, H1 2020
Chronic Urticaria Or Hives - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Chronic Urticaria Or Hives - Pipeline by Faes Farma SA, H1 2020
Chronic Urticaria Or Hives - Pipeline by Genentech Inc, H1 2020
Chronic Urticaria Or Hives - Pipeline by GI Innovation Co Ltd, H1 2020
Chronic Urticaria Or Hives - Pipeline by GlaxoSmithKline Plc, H1 2020
Chronic Urticaria Or Hives - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2020
Chronic Urticaria Or Hives - Pipeline by Gossamer Bio Inc, H1 2020
Chronic Urticaria Or Hives - Pipeline by Kolmar Korea Holdings Co Ltd, H1 2020
Chronic Urticaria Or Hives - Pipeline by Kyowa Kirin Co Ltd, H1 2020
Chronic Urticaria Or Hives - Pipeline by Mabtech Ltd, H1 2020
Chronic Urticaria Or Hives - Pipeline by Mycenax Biotech Inc, H1 2020
Chronic Urticaria Or Hives - Pipeline by Novartis AG, H1 2020
Chronic Urticaria Or Hives - Pipeline by Oneness Biotech Co Ltd, H1 2020
Chronic Urticaria Or Hives - Pipeline by PharmAbcine Inc, H1 2020
Chronic Urticaria Or Hives - Pipeline by RAPT Therapeutics Inc, H1 2020
Chronic Urticaria Or Hives - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Chronic Urticaria Or Hives - Pipeline by STERO Biotechs Ltd, H1 2020
Chronic Urticaria Or Hives - Pipeline by Synermore Biologics Co Ltd, H1 2020
Chronic Urticaria Or Hives - Pipeline by United Biomedical Inc, H1 2020
Chronic Urticaria Or Hives - Pipeline by United BioPharma Inc, H1 2020
Chronic Urticaria Or Hives - Dormant Projects, H1 2020
Chronic Urticaria Or Hives - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Chronic Urticaria Or Hives, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Allakos Inc
BiOraliX BV
BiosanaPharma BV
Celldex Therapeutics Inc
Celltrion Inc
Eli Lilly and Co
ELORAC Inc
F. Hoffmann-La Roche Ltd
Faes Farma SA
Genentech Inc
GI Innovation Co Ltd
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Gossamer Bio Inc
Kolmar Korea Holdings Co Ltd
Kyowa Kirin Co Ltd
Mabtech Ltd
Mycenax Biotech Inc
Novartis AG
Oneness Biotech Co Ltd
PharmAbcine Inc
RAPT Therapeutics Inc
Regeneron Pharmaceuticals Inc
STERO Biotechs Ltd
Synermore Biologics Co Ltd
United Biomedical Inc
United BioPharma Inc